Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04603001 |
|
Recruitment Status :
Recruiting
First Posted : October 26, 2020
Last Update Posted : March 11, 2021
|
Sponsor:
Loxo Oncology, Inc.
Collaborator:
Eli Lilly and Company
Information provided by (Responsible Party):
Loxo Oncology, Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | February 2023 |
| Estimated Study Completion Date : | September 2023 |